Biohaven Pharmaceutical (BHVN) Releases Quarterly Earnings Results, Misses Expectations By $1.20 EPS
Biohaven Pharmaceutical (NYSE:BHVN) issued its quarterly earnings results on Tuesday. The company reported ($2.32) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.12) by ($1.20), Bloomberg Earnings reports.
Biohaven Pharmaceutical traded up $0.21, reaching $29.98, during midday trading on Wednesday, Marketbeat Ratings reports. The company’s stock had a trading volume of 22,367 shares, compared to its average volume of 663,208. Biohaven Pharmaceutical has a fifty-two week low of $29.11 and a fifty-two week high of $30.31. The company has a market cap of $1.03 billion and a P/E ratio of -5.99.
Several equities research analysts recently weighed in on the company. Zacks Investment Research downgraded Biohaven Pharmaceutical from a “hold” rating to a “sell” rating in a report on Tuesday, January 30th. Canaccord Genuity reaffirmed a “buy” rating and set a $39.00 price target (up from $30.00) on shares of Biohaven Pharmaceutical in a report on Thursday, February 22nd. Needham & Company LLC reaffirmed a “buy” rating on shares of Biohaven Pharmaceutical in a report on Thursday, February 22nd. ValuEngine raised Biohaven Pharmaceutical from a “sell” rating to a “hold” rating in a report on Wednesday, May 2nd. Finally, Barclays downgraded Biohaven Pharmaceutical from an “overweight” rating to an “equal weight” rating and decreased their price target for the stock from $30.00 to $25.00 in a report on Thursday, April 5th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and five have given a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and an average price target of $37.14.
Biohaven Pharmaceutical Company Profile
Biohaven Pharmaceutical Holding Company Ltd., a clinical-stage biopharmaceutical company, develops product candidates to treat neurological diseases, including rare disorders. Its lead product candidate is rimegepant, which is in Phase III clinical trials for the acute treatment of migraine. The company also develops trigriluzole, which is in a Phase II/III clinical trial used for the treatment of ataxias with an initial focus on spinocerebellar ataxia; and Phase II/III clinical trial for the treatment of obsessive compulsive disorders, as well as for the treatment of Alzheimer's diseases.
Receive News & Ratings for Biohaven Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biohaven Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.